Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0D1VJ
|
||||
| Former ID |
DIB008502
|
||||
| Drug Name |
SDZ-210-086
|
||||
| Synonyms |
SDZ-BOP-086
|
||||
| Indication | Cognitive disorders [ICD9: 290-294, 294.0, 780.09, 780.9, 780.93; ICD10:F01-F07, F04, F05, R41.3] | Discontinued in Phase 1 | [1] | ||
| Company |
Novartis AG
|
||||
| Structure |
|
Download2D MOL |
|||
| Canonical SMILES |
O1C2(CCN(CC2)C)CO[C@@H]1C.C(=O)(/C=C\C(=O)O)O
|
||||
| CAS Number |
CAS 104925-23-7
|
||||
| Target and Pathway | |||||
| Target(s) | Muscarinic acetylcholine receptor M1 | Target Info | Agonist | [2] | |
| KEGG Pathway | Calcium signaling pathway | ||||
| cAMP signaling pathway | |||||
| Neuroactive ligand-receptor interaction | |||||
| PI3K-Akt signaling pathway | |||||
| Cholinergic synapse | |||||
| Regulation of actin cytoskeleton | |||||
| PANTHER Pathway | Alzheimer disease-amyloid secretase pathway | ||||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | |||||
| Muscarinic acetylcholine receptor 1 and 3 signaling pathway | |||||
| Reactome | Muscarinic acetylcholine receptors | ||||
| G alpha (q) signalling events | |||||
| WikiPathways | Monoamine GPCRs | ||||
| Calcium Regulation in the Cardiac Cell | |||||
| Regulation of Actin Cytoskeleton | |||||
| GPCRs, Class A Rhodopsin-like | |||||
| Gastrin-CREB signalling pathway via PKC and MAPK | |||||
| Secretion of Hydrochloric Acid in Parietal Cells | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001734) | ||||
| REF 2 | Influence of the cholinergic agonist SDZ 210-086 on sleep in healthy subjects. Neuropsychopharmacology. 1993 Nov;9(3):225-32. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.